Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Analyst Coverage
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

SEC Filings

SEC Filings

SEC Filing Keyword Search

Filing date Form Description Filing Group View
Jan 11, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-21-000724.pdf
0001564590-21-000724.rtf
0001564590-21-000724.xls
Dec 11, 2020 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-20-315880.pdf
0001193125-20-315880.rtf
0001193125-20-315880.xls
Dec 11, 2020 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
0001193125-20-315903.pdf
0001193125-20-315903.rtf
Dec 10, 2020 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-20-056631.pdf
0001564590-20-056631.rtf
0001564590-20-056631.xls
Nov 13, 2020 6-K/A

Amendment to a previously filed 6-K

Current Reports
View HTML
0001564590-20-053711.pdf
0001564590-20-053711.rtf
0001564590-20-053711.xls
Nov 09, 2020 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-20-052245.pdf
0001564590-20-052245.rtf
0001564590-20-052245.xls
Oct 09, 2020 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-20-267200.pdf
0001193125-20-267200.rtf
0001193125-20-267200.xls
EX-101.INS - XBRL INSTANCE DOCUMENT
Oct 09, 2020 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
0001193125-20-267301.pdf
0001193125-20-267301.rtf
0001193125-20-267301.xls
Sep 22, 2020 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-20-044147.pdf
0001564590-20-044147.rtf
0001564590-20-044147.xls
Sep 17, 2020 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-20-043862.pdf
0001564590-20-043862.rtf
0001564590-20-043862.xls

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Careers

ASLAN is always interested in hearing from outstanding candidates with a track record in developing innovative drugs, an entrepreneurial spirit and a passion for Asia.

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Tel: +65 6222 4235
Fax: +65 6225 2419

Taipei Office
Room 3711-15, 37F,
Taipei Nanshan Plaza, No.100,
Songren Rd, Xinyi District,
Taipei 110, Taiwan (R.O.C)
Tel: +886 2 3725 7770
Fax: +886 2 3725 7999
Investor relations Tel: +886 2 3725 7768

Shanghai Office
Room 1902 Jin Hang Tower,
No.83 Wan Hang Du Road,
Jing An District, Shanghai, China, 200040
Tel: +86 138 1707 7567
Fax: +86 21 6135 9428

Australia Office
58 Gipps Street, Collingwood
Victoria, 3066

contact@aslanpharma.com